A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about how tirzepatide affects the body's
 response to low blood sugar (hypoglycemia). The study is open to participants with type 2
 diabetes. It will last about 42 weeks for each participant.
Inclusion Criteria:

 -  Have type 2 diabetes mellitus (T2DM) for at least 1 year

 -  Treated with diet and exercise and stable dose(s) of metformin 3 months prior to study
 entry with or without 1 additional oral antidiabetic medication (OAM) other than
 metformin.

 -  Have a hemoglobin A1c (HbA1c) value at screening of ≥6.5% and ≤9.0 % if on metformin
 only.

 -  Have a HbA1c value at screening of ≥6.0% and ≤8.5 %, if on metformin and 1 more
 allowed OAM.

 -  Have a body mass index (BMI) between 23 and 45 kilograms per square meter (kg/m²)
 inclusive, at screening

 -  Are of stable weight (±5%) >3 months prior to screening

 Exclusion Criteria:

 -  Have a history of proliferative retinopathy or maculopathy as determined by the
 investigator based on a recent (<6 months) ophthalmologic examination

 -  Impaired renal estimated glomerular filtration rate (eGFR) <60 milliliters per minute
 per 1.73 square meters (mL/min/1.73 m²) calculated by Chronic Kidney Disease
 Epidemiology Collaboration (CKD-EPI)

 -  Have a history of or current cardiovascular, respiratory, hepatic, renal,
 gastrointestinal (GI), endocrine, hematological or neurological disorders capable of
 significantly altering the absorption, metabolism or elimination of drugs; of
 constituting a risk when taking the study drug; or of interfering with the
 interpretation of data

 -  Have had acute myocardial infarction, congestive heart failure New York Heart
 Association Class III or IV, history of or suspected ischemic heart disease, and/or
 cerebrovascular accident (stroke [including transient ischemic attack])